Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Ernexa Therapeutics Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Completed
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
IRX-2, Cyclophosphamide
Squamous Cell Carcinoma of the Head and Neck
NCT00210470Enrollment27StartJul 2005Primary CompletionDec 2010CompletionMar 2012 - Phase 2Completed
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
IRX-2, Cyclophosphamide
Squamous Cell Carcinoma of the Oral Cavity
NCT02609386Enrollment105StartJan 2016Primary CompletionFeb 2022CompletionFeb 2022
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Completed | IRX-2, Cyclophosphamide | NCT00210470 |
| Phase 2 | Completed | IRX-2, Cyclophosphamide | NCT02609386 |